Simplification of antiretroviral therapy: A necessary step in the public health response to HIV/AIDS in resource-limited settings

Antiviral Therapy

Volumn 19, Issue , 2014, Pages 31-37

  Vitoria, Marco ^a   Ford, Nathan ^a   Doherty, Meg ^a   Flexner, Charles ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; DRUG COMBINATION; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; GENERIC DRUG; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIFAMPICIN; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CD4+ T LYMPHOCYTE; DEVELOPING COUNTRY; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG APPROVAL; DRUG COMBINATION; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG THERAPY; DRUG TOLERABILITY; ECONOMICS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NONHUMAN; ORGANIZATION AND MANAGEMENT; PHARMACEUTICAL EQUIVALENCE; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PUBLIC HEALTH; QUALITY OF LIFE; RESOURCE MANAGEMENT; RISK FACTOR; SCALE UP; SKIN TOXICITY; STANDARDS; SUPPLY AND DISTRIBUTION; TREATMENT RESPONSE; TRENDS; TUBERCULOSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY; DRUGS, GENERIC; ECONOMICS; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH; STANDARDS; SUPPLY AND DISTRIBUTION; TRENDS; WORLD HEALTH ORGANIZATION;

EID: 84964290970     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2898     Document Type: Article

References (39)

1. WHO. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: WHO 2002.
2. WHO. Global update on HIV treatment 2013: results, impact and opportunities. Geneva: WHO report, in partnership with UNICEF and UNAIDS 2013.
3. Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, et al. Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:77-82.
4. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009;50:506-512.
5. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013;10:e1001418.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
7. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013;339:966-971.
8. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3:e438.
9. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a metaanalysis. Clin Infect Dis 2009;48:484-488.
10. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a singletablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51:163-174.
11. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010;24:2835-2840.
12. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010;24:87-96.
13. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health 2010;8:8.
14. Sherr K, Mussa A, Chilundo B, et al. Brain drain and health workforce distortions in Mozambique. PLoS ONE 2012;7:e35840.
15. Tankwanchi AB, Ozden C, Vermund SH. Physician emigration from sub-Saharan Africa to the United States: analysis of the 2011 AMA Physician Masterfile. PLoS Med 2013;10:e1001513.
16. Ramjan R, Vitoria M, Mills E, Hill A, Cooke G, Ford N. Patient and programme impact of fixed-dose combination antiretroviral therapy: a systematic review and metaanalysis. Trop Med Int Health 2014;19:501-513.
17. Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. The 2013 WHO guidelines for antiretroviral therapy: evidencebased recommendations to face new epidemic realities. Curr Opin HIV AIDS 2013;8:528-534.
18. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO 2013. (Accessed 10 February 2014.) Available from http://www.who.int/hiv/pub/guidelines/arv2013/en
19. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013;8:12-18.
20. HIV drug interactions website (University of Liverpool). Drug interactions charts. (Accessed 10 February 2014.) Available from http://www.hiv-druginteractions.org/Interactions.aspx
21. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based firstline antiretroviral therapy: a systematic review and metaanalysis. AIDS 2013;27:1403-1412.
22. Van Oosterhout JJ, Mallewa J, Kaunda S, et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS ONE 2012;7:e42029.
23. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011;11:244.
24. Duncombe C, Ball A, Passarelli C, Hirnschall G. Treatment 2.0: catalyzing the next phase of treatment, care and support. Curr Opin HIV AIDS 2013;8:4-11.
25. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005;65:413-432.
26. US Food and Drug Administration. Drugs@FDA. Viread. (Accessed 3 June 2012). Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search. DrugDetails
27. WHO. Technical Update on Treatment Optimization. Use of tenofovir in HIV-infected children and adolescents: a public health perspective. Geneva: WHO 2012. (Accessed 10 February 2014.) Available from http://www.who.int/hiv/pub/treatment2/tenofovir/en
28. Pillay P, Shubber Z, Ferrand R. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS ONE 2013;8:e68995.
29. WHO. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective. Geneva: WHO 2012. (Accessed 10 February 2014.) Available from http://www.who.int/hiv/pub/treatment2/efavirenz/en
30. WHO. WHO model lists of essential medicines. (Accessed 10 April 2014.) Available from http://www.who.int/medicines/publications/essentialmedicines/en/index.html
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 10 February 2014.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
32. WHO. Technical update on treatment optimization. Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. Geneva: WHO 2012. (Accessed 10 February 2014.) Available from http://www.who.int/hiv/pub/treatment2/lamivudine-emtricibatine/en
33. Andrieux-Meyer I, Calmy A, Cahn P, et al. Preferred antiretroviral drugs for the next decade of scale up. J Int AIDS Soc 2012;15:17986.
34. WHO. WHO informal consultation on medium- and longterm priorities for ARV drug optimization. Moving towards simplification, harmonization and universal access. Geneva: WHO 2012. (Accessed 10 February 2014.) Available from http://www.who.int/hiv/pub/meetingreports/think-tank/en
35. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and metaanalysis. PLoS ONE 2013;8:e68995.
36. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011;378:1572-1579.
37. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013;158:84-92.
38. Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev 2013;6: CD009987.
39. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr 2011;56:e39-e44.